CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma
Liver cancer, especially hepatocellular carcinoma, is an important cause of cancer-related death, and its incidence is increasing worldwide. Nano drug delivery systems have shown great promise in the treatment of cancers. In order to improve their therapeutic efficacy, it is very important to realiz...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/2/426 |
| _version_ | 1797618771821592576 |
|---|---|
| author | Jinhu Liu Weiwei Mu Tong Gao Yuxiao Fang Na Zhang Yongjun Liu |
| author_facet | Jinhu Liu Weiwei Mu Tong Gao Yuxiao Fang Na Zhang Yongjun Liu |
| author_sort | Jinhu Liu |
| collection | DOAJ |
| description | Liver cancer, especially hepatocellular carcinoma, is an important cause of cancer-related death, and its incidence is increasing worldwide. Nano drug delivery systems have shown great promise in the treatment of cancers. In order to improve their therapeutic efficacy, it is very important to realize the high accumulation and effective release of drugs at the tumor site. In this manuscript, using doxorubicin (DOX) as a model drug, CD13-targeted mesoporous silica nanoparticles coated with NGR-peptide-modified pegylated carboxymethyl chitosan were constructed (DOX/MSN-CPN). DOX/MSN-CPN comprises a spherical shape with an obvious capping structure and a particle size of 125.01 ± 1.52 nm. With a decrease in pH, DOX/MSN-CPN showed responsive desorption from DOX/MSN-CPN and pH-responsive release of DOX was observed. Meanwhile, DOX/MSN-CPN could be efficiently absorbed through NGR-mediated internalization in vitro and could efficiently deliver DOX to tumor tissues with long accumulation times in vivo, suggesting good active targeting properties. Moreover, significant tumor inhibition has been observed in antitumor studies in vivo. This study provides a strategy of utilizing DOX/MSN-CPN as a nano-platform for drug delivery, which has superb therapeutic efficacy and safety for the treatment of hepatocellular carcinoma both in vivo and in vitro. |
| first_indexed | 2024-03-11T08:17:18Z |
| format | Article |
| id | doaj.art-c4d4e60533a040fb8b3f7b3e18959bc6 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T08:17:18Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-c4d4e60533a040fb8b3f7b3e18959bc62023-11-16T22:39:47ZengMDPI AGPharmaceutics1999-49232023-01-0115242610.3390/pharmaceutics15020426CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular CarcinomaJinhu Liu0Weiwei Mu1Tong Gao2Yuxiao Fang3Na Zhang4Yongjun Liu5Department of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaDepartment of Pharmaceutics, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, ChinaLiver cancer, especially hepatocellular carcinoma, is an important cause of cancer-related death, and its incidence is increasing worldwide. Nano drug delivery systems have shown great promise in the treatment of cancers. In order to improve their therapeutic efficacy, it is very important to realize the high accumulation and effective release of drugs at the tumor site. In this manuscript, using doxorubicin (DOX) as a model drug, CD13-targeted mesoporous silica nanoparticles coated with NGR-peptide-modified pegylated carboxymethyl chitosan were constructed (DOX/MSN-CPN). DOX/MSN-CPN comprises a spherical shape with an obvious capping structure and a particle size of 125.01 ± 1.52 nm. With a decrease in pH, DOX/MSN-CPN showed responsive desorption from DOX/MSN-CPN and pH-responsive release of DOX was observed. Meanwhile, DOX/MSN-CPN could be efficiently absorbed through NGR-mediated internalization in vitro and could efficiently deliver DOX to tumor tissues with long accumulation times in vivo, suggesting good active targeting properties. Moreover, significant tumor inhibition has been observed in antitumor studies in vivo. This study provides a strategy of utilizing DOX/MSN-CPN as a nano-platform for drug delivery, which has superb therapeutic efficacy and safety for the treatment of hepatocellular carcinoma both in vivo and in vitro.https://www.mdpi.com/1999-4923/15/2/426mesoporous silica nanoparticleNGR peptidepegylated carboxymethyl chitosantriggered releasehepatocellular carcinoma |
| spellingShingle | Jinhu Liu Weiwei Mu Tong Gao Yuxiao Fang Na Zhang Yongjun Liu CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma Pharmaceutics mesoporous silica nanoparticle NGR peptide pegylated carboxymethyl chitosan triggered release hepatocellular carcinoma |
| title | CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma |
| title_full | CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma |
| title_fullStr | CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma |
| title_full_unstemmed | CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma |
| title_short | CD13-Mediated Pegylated Carboxymethyl Chitosan-Capped Mesoporous Silica Nanoparticles for Enhancing the Therapeutic Efficacy of Hepatocellular Carcinoma |
| title_sort | cd13 mediated pegylated carboxymethyl chitosan capped mesoporous silica nanoparticles for enhancing the therapeutic efficacy of hepatocellular carcinoma |
| topic | mesoporous silica nanoparticle NGR peptide pegylated carboxymethyl chitosan triggered release hepatocellular carcinoma |
| url | https://www.mdpi.com/1999-4923/15/2/426 |
| work_keys_str_mv | AT jinhuliu cd13mediatedpegylatedcarboxymethylchitosancappedmesoporoussilicananoparticlesforenhancingthetherapeuticefficacyofhepatocellularcarcinoma AT weiweimu cd13mediatedpegylatedcarboxymethylchitosancappedmesoporoussilicananoparticlesforenhancingthetherapeuticefficacyofhepatocellularcarcinoma AT tonggao cd13mediatedpegylatedcarboxymethylchitosancappedmesoporoussilicananoparticlesforenhancingthetherapeuticefficacyofhepatocellularcarcinoma AT yuxiaofang cd13mediatedpegylatedcarboxymethylchitosancappedmesoporoussilicananoparticlesforenhancingthetherapeuticefficacyofhepatocellularcarcinoma AT nazhang cd13mediatedpegylatedcarboxymethylchitosancappedmesoporoussilicananoparticlesforenhancingthetherapeuticefficacyofhepatocellularcarcinoma AT yongjunliu cd13mediatedpegylatedcarboxymethylchitosancappedmesoporoussilicananoparticlesforenhancingthetherapeuticefficacyofhepatocellularcarcinoma |